{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:04:06Z","timestamp":1789585446987,"version":"build-2803163510"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Frankfurt Cancer Institute, the parents Association \u201cHilfe f\u00fcr Krebskranke Kinder e.V.\" C3OMBAT consortium. the Frankfurt Foundation for Children with Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly improved the outcome of children with high-risk (HR) acute myeloid leukemia (AML). Implementing allogeneic HSCT depends on numerous factors, including adverse cytogenetics, molecular abnormalities, poor response to first-line treatment, or relapsed or primary refractory disease. In HR AML, allogeneic HSCT is considered to be the consolidation strategy of choice in first complete remission (CR1) and offers the best chance of cure for patients with relapsed disease. Advances in donor\/recipient typing, conditioning regimens, graft-versus-host-disease (GvHD) management, and supportive care have contributed to this improvement in overall\u2014and transplant\u2014outcome. This review will comprehensively discuss indications for HSCT and its modalities in pediatric AML by examining past, current, and future strategies for disease- and response-related stratification. We will examine the key importance of low\/negative measurable residual disease (MRD) before transplantation and discuss conditioning regimens and graft variables, as well as novel approaches to harness the graft-versus-leukemia (GvL) effect, including targeted immunotherapy. The review will also address toxicities associated with HSCT, GvHD prophylaxis, and the management of treatment failure. Ultimately, this review seeks to inform clinical practice and highlights how improved outcomes have been achieved through the collective efforts of international study groups.<\/jats:p>","DOI":"10.1038\/s41375-025-02685-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:53:18Z","timestamp":1752137598000},"page":"2313-2328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2213-2838","authenticated-orcid":false,"given":"Eva","family":"Rettinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Heckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2151-8342","authenticated-orcid":false,"given":"Martin","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0386-0714","authenticated-orcid":false,"given":"Dominik","family":"Turkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kleinschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-4483","authenticated-orcid":false,"given":"Dirk","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0727","authenticated-orcid":false,"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2685_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28979","volume":"68","author":"G Egan","year":"2021","unstructured":"Egan G, Chopra Y, Mourad S, Chiang KY, Hitzler J. Treatment of acute myeloid leukemia in children: a practical perspective. Pediatr Blood Cancer. 2021;68:e28979.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1703601","volume":"30","author":"M Bleakley","year":"2002","unstructured":"Bleakley M, Shaw PJ, Nielsen JM. Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor. Bone Marrow Transplant. 2002;30:1\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.bmt.1703528","volume":"29","author":"M Bleakley","year":"2002","unstructured":"Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant. 2002;29:843\u201352.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2010-01-261800","volume":"116","author":"D Niewerth","year":"2010","unstructured":"Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205\u201314.","journal-title":"Blood"},{"key":"2685_CR5","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949\u201362.","journal-title":"J Clin Oncol"},{"key":"2685_CR6","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187\u2013205.","journal-title":"Blood"},{"key":"2685_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1046\/j.1365-2141.2003.04418.x","volume":"122","author":"SO Lie","year":"2003","unstructured":"Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down\u2019s syndrome: results of NOPHO-AML trials. Br J Haematol. 2003;122:217\u201325.","journal-title":"Br J Haematol"},{"key":"2685_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00277-022-04965-x","volume":"101","author":"R Masetti","year":"2022","unstructured":"Masetti R, Muratore E, Gori D, Prete A, Locatelli F. Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. Ann Hematol. 2022;101:2497\u2013506.","journal-title":"Ann Hematol"},{"key":"2685_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-019-00502-2","volume":"14","author":"P Merli","year":"2019","unstructured":"Merli P, Algeri M, Del Bufalo F, Locatelli F. Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2019;14:94\u2013105.","journal-title":"Curr Hematol Malig Rep"},{"key":"2685_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1399-3046.2008.00997.x","volume":"13","author":"DH Lee","year":"2009","unstructured":"Lee DH, Kwon YJ, Lim J, Kim Y, Han K, Chung NG, et al. Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatr Transplant. 2009;13:210\u20136.","journal-title":"Pediatr Transplant"},{"key":"2685_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.bbmt.2007.01.073","volume":"13","author":"J Moore","year":"2007","unstructured":"Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007;13:601\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR12","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1200\/JCO.2007.13.5244","volume":"26","author":"JT Horan","year":"2008","unstructured":"Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children\u2019s Oncology Group. J Clin Oncol. 2008;26:5797\u2013801.","journal-title":"J Clin Oncol"},{"key":"2685_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2685_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2685_CR15","doi-asserted-by":"crossref","unstructured":"Algeri M, Merli P, Locatelli F, Pagliara D. The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. J Clin Med. 2021;10:3790.","DOI":"10.3390\/jcm10173790"},{"key":"2685_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.12900","volume":"166","author":"H Hasle","year":"2014","unstructured":"Hasle H. A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol. 2014;166:23\u201333.","journal-title":"Br J Haematol"},{"key":"2685_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/pbc.24739","volume":"61","author":"MJ Kelly","year":"2014","unstructured":"Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W, et al. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatr Blood Cancer. 2014;61:269\u201375.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhauser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2685_CR19","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","volume":"28","author":"CJ Harrison","year":"2010","unstructured":"Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28:2674\u201381.","journal-title":"J Clin Oncol"},{"key":"2685_CR20","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","volume":"28","author":"C von Neuhoff","year":"2010","unstructured":"von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28:2682\u20139.","journal-title":"J Clin Oncol"},{"key":"2685_CR21","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2014;32:3021\u201332.","journal-title":"J Clin Oncol"},{"key":"2685_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","volume":"118","author":"AK Burnett","year":"2002","unstructured":"Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385\u2013400.","journal-title":"Br J Haematol"},{"key":"2685_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41409-024-02197-3","volume":"59","author":"A Sharma","year":"2024","unstructured":"Sharma A, Galimard JE, Pryce A, Bhoopalan SV, Dalissier A, Dalle JH, et al. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP\/EBMT study. Bone Marrow Transplant. 2024;59:451\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR24","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties. Blood. 1998;92:2322\u201333.","journal-title":"Blood"},{"key":"2685_CR25","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1182\/blood-2006-10-051342","volume":"109","author":"H Hasle","year":"2007","unstructured":"Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109:4641\u20137.","journal-title":"Blood"},{"key":"2685_CR26","doi-asserted-by":"crossref","unstructured":"Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M. Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge. Genes. 2021;12:924.","DOI":"10.3390\/genes12060924"},{"key":"2685_CR27","first-page":"2331","volume":"108","author":"G Richard-Carpentier","year":"2023","unstructured":"Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, et al. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023;108:2331\u201342.","journal-title":"Haematologica"},{"key":"2685_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","volume":"157","author":"S Groschel","year":"2014","unstructured":"Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157:369\u201381.","journal-title":"Cell"},{"key":"2685_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","volume":"25","author":"H Yamazaki","year":"2014","unstructured":"Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25:415\u201327.","journal-title":"Cancer Cell"},{"key":"2685_CR30","volume":"2023","author":"C Blakemore","year":"2023","unstructured":"Blakemore C, Damodharan S, Puccetti D. Inv(3) acute myeloid leukemia in a young adult and review of the literature. Case Rep Oncol Med. 2023;2023:6628492.","journal-title":"Case Rep Oncol Med"},{"key":"2685_CR31","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489\u201396.","journal-title":"Blood"},{"key":"2685_CR32","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the Phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2021;39:3149\u201360.","journal-title":"J Clin Oncol"},{"key":"2685_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","volume":"39","author":"SE Conneely","year":"2020","unstructured":"Conneely SE, Rau RE. The genomics of acute myeloid leukemia in children. Cancer Metastasis Rev. 2020;39:189\u2013209.","journal-title":"Cancer Metastasis Rev"},{"key":"2685_CR34","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2023;41:2963\u201374.","journal-title":"J Clin Oncol"},{"key":"2685_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3324\/haematol.2011.051714","volume":"97","author":"JH Klusmann","year":"2012","unstructured":"Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica. 2012;97:21\u201329.","journal-title":"Haematologica"},{"key":"2685_CR36","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/cam4.5026","volume":"12","author":"KY Yuen","year":"2023","unstructured":"Yuen KY, Liu Y, Zhou YZ, Wang Y, Zhou DH, Fang JP, et al. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23\/KMT2A rearrangements. Cancer Med. 2023;12:1418\u201330.","journal-title":"Cancer Med"},{"key":"2685_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ajh.25859","volume":"95","author":"M Byrne","year":"2020","unstructured":"Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95:1006\u201314.","journal-title":"Am J Hematol"},{"key":"2685_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5265-5","volume":"19","author":"M Piedimonte","year":"2019","unstructured":"Piedimonte M, Ottone T, Alfonso V, Ferrari A, Conte E, Divona M, et al. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. BMC Cancer. 2019;19:50.","journal-title":"BMC Cancer"},{"key":"2685_CR39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1365-2141.2010.08472.x","volume":"152","author":"U Bacher","year":"2011","unstructured":"Bacher U, Haferlach T, Alpermann T, Zenger M, Hochhaus A, Beelen DW, et al. Subclones with the t(9;22)\/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol. 2011;152:713\u201320.","journal-title":"Br J Haematol"},{"key":"2685_CR40","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00277-016-2721-z","volume":"95","author":"NR Neuendorff","year":"2016","unstructured":"Neuendorff NR, Burmeister T, Dorken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol. 2016;95:1211\u201321.","journal-title":"Ann Hematol"},{"key":"2685_CR41","doi-asserted-by":"publisher","unstructured":"Buteyn NJ, Burke CG, Sartori VJ, Deering-Gardner E, DeBruine ZJ, Kamarudin D, et al. EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion. bioRxiv [Preprint]. 2024. https:\/\/doi.org\/10.1101\/2024.05.14.594150.","DOI":"10.1101\/2024.05.14.594150"},{"key":"2685_CR42","doi-asserted-by":"publisher","unstructured":"Zhang Z, Sun C, Cai L, Chen Y, Zhou X, Chen S, et al. Prognostic factors in Philadelphia chromosome-positive acute myeloid leukemia using fluorescence in situ hybridization. Clin Lab. 2024;70. https:\/\/doi.org\/10.7754\/Clin.Lab.2023.230645","DOI":"10.7754\/Clin.Lab.2023.230645"},{"key":"2685_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.12852","volume":"166","author":"K Tarlock","year":"2014","unstructured":"Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, et al. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children\u2019s Oncology Group. Br J Haematol. 2014;166:254\u20139.","journal-title":"Br J Haematol"},{"key":"2685_CR44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/leu.2011.229","volume":"26","author":"K Ishiyama","year":"2012","unstructured":"Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T, et al. Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. Leukemia. 2012;26:461\u20134.","journal-title":"Leukemia"},{"key":"2685_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2013.098517","volume":"99","author":"JD Sandahl","year":"2014","unstructured":"Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, et al. t(6;9)(p22;q34)\/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014;99:865\u201372.","journal-title":"Haematologica"},{"key":"2685_CR46","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","volume":"118","author":"IH Hollink","year":"2011","unstructured":"Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118:3645\u201356.","journal-title":"Blood"},{"key":"2685_CR47","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1182\/blood-2014-04-570929","volume":"124","author":"F Ostronoff","year":"2014","unstructured":"Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, et al. NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014;124:2400\u20137.","journal-title":"Blood"},{"key":"2685_CR48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/gcc.22064","volume":"52","author":"N Shiba","year":"2013","unstructured":"Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer. 2013;52:683\u201393.","journal-title":"Genes Chromosomes Cancer"},{"key":"2685_CR49","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/gcc.22444","volume":"56","author":"Y Hara","year":"2017","unstructured":"Hara Y, Shiba N, Ohki K, Tabuchi K, Yamato G, Park MJ, et al. Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome. Genes Chromosomes Cancer. 2017;56:394\u2013404.","journal-title":"Genes Chromosomes Cancer"},{"key":"2685_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/jcm4010127","volume":"4","author":"JD de Rooij","year":"2015","unstructured":"de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: from biology to clinical management. J Clin Med. 2015;4:127\u201349.","journal-title":"J Clin Med"},{"key":"2685_CR51","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3324\/haematol.2022.281653","volume":"108","author":"EJM Bertrums","year":"2023","unstructured":"Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108:2044\u201358.","journal-title":"Haematologica"},{"key":"2685_CR52","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","volume":"127","author":"JD de Rooij","year":"2016","unstructured":"de Rooij JD, Masetti R, van den Heuvel-Eibrink MM, Cayuela JM, Trka J, Reinhardt D, et al. Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood. 2016;127:3424\u201330.","journal-title":"Blood"},{"key":"2685_CR53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/gcc.22538","volume":"57","author":"ADL Espersen","year":"2018","unstructured":"Espersen ADL, Noren-Nystrom U, Abrahamsson J, Ha SY, Pronk CJ, Jahnukainen K, et al. Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: data from Nordic Society for Pediatric Hematology and Oncology (NOPHO-AML) and review of the literature. Genes Chromosomes Cancer. 2018;57:359\u201365.","journal-title":"Genes Chromosomes Cancer"},{"key":"2685_CR54","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/blood-2013-02-485524","volume":"122","author":"EA Coenen","year":"2013","unstructured":"Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Haas V, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood. 2013;122:2704\u201313.","journal-title":"Blood"},{"key":"2685_CR55","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3324\/haematol.2014.104182","volume":"99","author":"U Creutzig","year":"2014","unstructured":"Creutzig U, Zimmermann M, Dworzak MN, Gibson B, Tamminga R, Abrahamsson J, et al. The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001\/01. Haematologica. 2014;99:1472\u20138.","journal-title":"Haematologica"},{"key":"2685_CR56","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033\u201340.","journal-title":"Blood"},{"key":"2685_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31489-9","volume":"13","author":"KY Qiu","year":"2022","unstructured":"Qiu KY, Liao XY, Liu Y, Huang K, Li Y, Fang JP, et al. Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3\/ITD allelic ratios. Nat Commun. 2022;13:3679.","journal-title":"Nat Commun"},{"key":"2685_CR58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s12887-024-05007-3","volume":"24","author":"JW Wang","year":"2024","unstructured":"Wang JW, Yu L, Yang XG, Xu LH. NUP98::NSD1 and FLT3\/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients. BMC Pediatr. 2024;24:547.","journal-title":"BMC Pediatr"},{"key":"2685_CR59","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105:1507\u201316.","journal-title":"Haematologica"},{"key":"2685_CR60","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1182\/blood-2008-09-177949","volume":"113","author":"IH Hollink","year":"2009","unstructured":"Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113:5951\u201360.","journal-title":"Blood"},{"key":"2685_CR61","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","volume":"108","author":"S Meshinchi","year":"2006","unstructured":"Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108:3654\u201361.","journal-title":"Blood"},{"key":"2685_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/leu.2016.177","volume":"31","author":"E Manara","year":"2017","unstructured":"Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, et al. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 Study Group. Leukemia. 2017;31:18\u201325.","journal-title":"Leukemia"},{"key":"2685_CR63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbmt.2014.08.008","volume":"21","author":"T Schechter","year":"2015","unstructured":"Schechter T, Gassas A, Chen H, Pollard J, Meshinchi S, Zaidman I, et al. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. Biol Blood Marrow Transplant. 2015;21:172\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR64","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124:3441\u20139.","journal-title":"Blood"},{"key":"2685_CR65","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121:2734\u20138.","journal-title":"Blood"},{"key":"2685_CR66","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/bloodadvances.2023011869","volume":"8","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Zhao D, Zarif M, Davidson MB, Minden MD, Tierens A, et al. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria. Blood Adv. 2024;8:1760\u201371.","journal-title":"Blood Adv"},{"key":"2685_CR67","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1182\/blood-2017-09-765214","volume":"131","author":"F Locatelli","year":"2018","unstructured":"Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood. 2018;131:1406\u201314.","journal-title":"Blood"},{"key":"2685_CR68","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.canep.2015.06.009","volume":"39","author":"MJ Hossain","year":"2015","unstructured":"Hossain MJ, Xie L, Caywood EH. Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: evidence from four decades of US population data. Cancer Epidemiol. 2015;39:720\u20136.","journal-title":"Cancer Epidemiol"},{"key":"2685_CR69","doi-asserted-by":"crossref","unstructured":"Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2007;1:392\u20137.","DOI":"10.1182\/asheducation-2007.1.392"},{"key":"2685_CR70","doi-asserted-by":"crossref","unstructured":"Sendker S, Schneider M, Antoniou E, Neumann D, Niktoreh N, Dirksen U, et al. Improved outcome and therapeutic directions in pediatric therapy-related AML: recommendations by the AML-BFM Study Group. Blood Adv. 2025;9:2831\u201341.","DOI":"10.1182\/bloodadvances.2024014728"},{"key":"2685_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbmt.2011.11.009","volume":"18","author":"R Kobos","year":"2012","unstructured":"Kobos R, Steinherz PG, Kernan NA, Prockop SE, Scaradavou A, Small TN, et al. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012;18:473\u201380.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR72","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41409-018-0157-x","volume":"53","author":"A Gassas","year":"2018","unstructured":"Gassas A, Sivaprakasam P, Cummins M, Breslin P, Patrick K, Slatter M, et al. High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group. Bone Marrow Transplant. 2018;53:1165\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR73","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.beha.2019.02.011","volume":"32","author":"YF Madanat","year":"2019","unstructured":"Madanat YF, Gerds AT. Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia? Best Pract Res Clin Haematol. 2019;32:104\u201313.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2685_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2017.01.024","volume":"55","author":"M Annereau","year":"2017","unstructured":"Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, et al. Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. Leuk Res. 2017;55:58\u201364.","journal-title":"Leuk Res"},{"key":"2685_CR75","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"key":"2685_CR76","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"2685_CR77","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2685_CR78","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3324\/haematol.2018.195289","volume":"104","author":"A Tuval","year":"2019","unstructured":"Tuval A, Shlush LI. Evolutionary trajectory of leukemic clones and its clinical implications. Haematologica. 2019;104:872\u201380.","journal-title":"Haematologica"},{"key":"2685_CR79","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","volume":"11","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543\u201352.","journal-title":"Lancet Oncol"},{"key":"2685_CR80","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fped.2019.00412","volume":"7","author":"B Buldini","year":"2019","unstructured":"Buldini B, Maurer-Granofszky M, Varotto E, Dworzak MN. Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies. Front Pediatr. 2019;7:412.","journal-title":"Front Pediatr"},{"key":"2685_CR81","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bjh.14093","volume":"174","author":"A Tierens","year":"2016","unstructured":"Tierens A, Bjorklund E, Siitonen S, Marquart HV, Wulff-Juergensen G, Pelliniemi TT, et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. Br J Haematol. 2016;174:600\u20139.","journal-title":"Br J Haematol"},{"key":"2685_CR82","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","volume":"120","author":"MR Loken","year":"2012","unstructured":"Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group. Blood. 2012;120:1581\u20138.","journal-title":"Blood"},{"key":"2685_CR83","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1182\/bloodadvances.2022009534","volume":"7","author":"SE Karol","year":"2023","unstructured":"Karol SE, Coustan-Smith E, Pounds S, Wang L, Inaba H, Ribeiro RC, et al. Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia. Blood Adv. 2023;7:3651\u20137.","journal-title":"Blood Adv"},{"key":"2685_CR84","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/leu.2010.153","volume":"24","author":"VH van der Velden","year":"2010","unstructured":"van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol. Leukemia. 2010;24:1599\u2013606.","journal-title":"Leukemia"},{"key":"2685_CR85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.14523","volume":"177","author":"B Buldini","year":"2017","unstructured":"Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol. Br J Haematol. 2017;177:116\u201326.","journal-title":"Br J Haematol"},{"key":"2685_CR86","doi-asserted-by":"crossref","unstructured":"Benetton M, Merli P, Walter C, Hansen M, Da Ros A, Polato K, et al. Molecular measurable residual disease assessment before hematopoietic stem cell transplantation in pediatric acute myeloid leukemia patients: a retrospective study by the I-BFM Study Group. Biomedicines. 2022;10:1530.","DOI":"10.3390\/biomedicines10071530"},{"key":"2685_CR87","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.05.4312","volume":"24","author":"C Langebrake","year":"2006","unstructured":"MRD-AML-BFM Study Group, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol. 2006;24:3686\u201392.","journal-title":"J Clin Oncol"},{"key":"2685_CR88","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2002-10-3064","volume":"101","author":"EL Sievers","year":"2003","unstructured":"Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children\u2019s Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101:3398\u2013406.","journal-title":"Blood"},{"key":"2685_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106954","volume":"122","author":"JP Meena","year":"2022","unstructured":"Meena JP, Pathak N, Gupta AK, Bakhshi S, Gupta R, Makkar H, et al. Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia. Leuk Res. 2022;122:106954.","journal-title":"Leuk Res"},{"key":"2685_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666470","volume":"11","author":"M Ruan","year":"2021","unstructured":"Ruan M, Liu L, Qi B, Chen X, Chang L, Zhang A, et al. Targeted next-generation sequencing of circulating tumor DNA, bone marrow, and peripheral blood mononuclear cells in pediatric AML. Front Oncol. 2021;11:666470.","journal-title":"Front Oncol"},{"key":"2685_CR91","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12185-022-03402-z","volume":"116","author":"X Chen","year":"2022","unstructured":"Chen X, Liu L, Zhang A, Yi M, Lan Y, Zheng Z, et al. Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia. Int J Hematol. 2022;116:669\u201377.","journal-title":"Int J Hematol"},{"key":"2685_CR92","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/bmt.2017.3","volume":"52","author":"P O\u2019Hare","year":"2017","unstructured":"O\u2019Hare P, Lucchini G, Cummins M, Veys P, Potter M, Lawson S, et al. Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience. Bone Marrow Transplant. 2017;52:825\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR93","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bjh.13611","volume":"171","author":"P Quarello","year":"2015","unstructured":"Quarello P, Fagioli F, Basso G, Putti MC, Berger M, Luciani M, et al. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002\/01 clinical trial. Br J Haematol. 2015;171:566\u201373.","journal-title":"Br J Haematol"},{"key":"2685_CR94","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/sj.bmt.1704689","volume":"34","author":"ER Nemecek","year":"2004","unstructured":"Nemecek ER, Gooley TA, Woolfrey AE, Carpenter PA, Matthews DC, Sanders JE. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant. 2004;34:799\u2013806.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR95","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730\u20138.","journal-title":"J Clin Oncol"},{"key":"2685_CR96","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41409-019-0461-0","volume":"54","author":"Y Okamoto","year":"2019","unstructured":"Okamoto Y, Kudo K, Tabuchi K, Tomizawa D, Taga T, Goto H, et al. Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplant. 2019;54:1489\u201398.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR97","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/pbc.22612","volume":"55","author":"MF Gorman","year":"2010","unstructured":"Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010;55:421\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR98","first-page":"2275","volume":"108","author":"G Egan","year":"2023","unstructured":"Egan G, Tasian SK. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica. 2023;108:2275\u201388.","journal-title":"Haematologica"},{"key":"2685_CR99","first-page":"928","volume":"65","author":"H Moritake","year":"2024","unstructured":"Moritake H. [Pediatric acute myeloid leukemia]. Rinsho Ketsueki. 2024;65:928\u201336.","journal-title":"Rinsho Ketsueki"},{"key":"2685_CR100","doi-asserted-by":"crossref","unstructured":"Strachan DC, Gu CJ, Kita R, Anderson EK, Richardson MA, Yam G, et al. Ex vivo drug sensitivity correlates with clinical response and supports personalized therapy in pediatric AML. Cancers. 2022;14:6240.","DOI":"10.3390\/cancers14246240"},{"key":"2685_CR101","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/OTT.S263829","volume":"16","author":"NE Wijnen","year":"2023","unstructured":"Wijnen NE, Koedijk JB, Klein K, Luesink M, Goemans BF, Zwaan CM, et al. Treating CD33-positive de novo acute myeloid leukemia in pediatric patients: focus on the clinical value of gemtuzumab ozogamicin. Onco Targets Ther. 2023;16:297\u2013308.","journal-title":"Onco Targets Ther"},{"key":"2685_CR102","first-page":"812 e811","volume":"30","author":"T Takahashi","year":"2024","unstructured":"Takahashi T, Lake AJ, Wachter F, Calderon FA, Dandoy C, Keating AK. Effects of total body irradiation on hematopoietic cell transplantation outcomes in pediatric acute myeloid leukemia with prior central nervous system involvement. Transplant Cell Ther. 2024;30:812 e811\u20132.","journal-title":"Transplant Cell Ther"},{"key":"2685_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1505247","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang X, Liu Y, Li Y. A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia. Front Immunol. 2025;16:1505247.","journal-title":"Front Immunol"},{"key":"2685_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200944","volume":"33","author":"QR Bubb","year":"2025","unstructured":"Bubb QR, Balood M, Seir GE, Swartzrock L, Haslett E, Ho K, et al. Development of multivalent CAR T cells as dual immunotherapy and conditioning agents. Mol Ther Oncol. 2025;33:200944.","journal-title":"Mol Ther Oncol"},{"key":"2685_CR105","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed YY. Revumenib: first approval. Drugs. 2025;85:577\u201383.","journal-title":"Drugs"},{"key":"2685_CR106","doi-asserted-by":"crossref","unstructured":"Rasche M, Zimmermann M, Steidel E, Alonzo T, Aplenc R, Bourquin JP, et al. Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG. Cancers. 2021;13:2336.","DOI":"10.3390\/cancers13102336"},{"key":"2685_CR107","doi-asserted-by":"crossref","unstructured":"Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, et al. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020;34:613\u201324.","DOI":"10.1038\/s41375-019-0584-8"},{"key":"2685_CR108","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","volume":"132","author":"A Bertaina","year":"2018","unstructured":"Bertaina A, Zecca M, Buldini B, Sacchi N, Algeri M, Saglio F, et al. Unrelated donor vs HLA-haploidentical alpha\/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood. 2018;132:2594\u2013607.","journal-title":"Blood"},{"key":"2685_CR109","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3324\/haematol.2024.285345","volume":"109","author":"A Ruggeri","year":"2024","unstructured":"Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109:2122\u201330.","journal-title":"Haematologica"},{"key":"2685_CR110","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.bbmt.2018.06.010","volume":"24","author":"DA Jacobsohn","year":"2018","unstructured":"Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, et al. Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biol Blood Marrow Transplant. 2018;24:2040\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR111","doi-asserted-by":"publisher","first-page":"963689723118355","DOI":"10.1177\/09636897231183559","volume":"32","author":"B Wang","year":"2023","unstructured":"Wang B, Wen X, Zhang R, Zhu G, Wu Y, Zhang Y, et al. Homoharringtonine-based induction therapy reduces the recurrence rate of pediatric acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Cell Transplant. 2023;32:9636897231183559.","journal-title":"Cell Transplant"},{"key":"2685_CR112","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1200\/JCO.23.01841","volume":"42","author":"A Tierens","year":"2024","unstructured":"Tierens A, Arad-Cohen N, Cheuk D, De Moerloose B, Fernandez Navarro JM, Hasle H, et al. Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease. J Clin Oncol. 2024;42:2174\u201385.","journal-title":"J Clin Oncol"},{"key":"2685_CR113","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.bbmt.2017.05.011","volume":"23","author":"M Bitan","year":"2017","unstructured":"Bitan M, Ahn KW, Millard HR, Pulsipher MA, Abdel-Azim H, Auletta JJ, et al. Personalized prognostic risk score for long-term survival for children with acute leukemia after allogeneic transplantation. Biol Blood Marrow Transplant. 2017;23:1523\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR114","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00432-021-03761-w","volume":"148","author":"C Pochon","year":"2022","unstructured":"Pochon C, Detrait M, Dalle JH, Michel G, Dhedin N, Chalandon Y, et al. Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). J Cancer Res Clin Oncol. 2022;148:2083\u201397.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2685_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00479-3","volume":"11","author":"MH Gilleece","year":"2021","unstructured":"Gilleece MH, Shimoni A, Labopin M, Robinson S, Beelen D, Socie G, et al. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer J. 2021;11:88.","journal-title":"Blood Cancer J"},{"key":"2685_CR116","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.bulcan.2024.02.006","volume":"112","author":"C Renard","year":"2025","unstructured":"Renard C, Corbel A, Paillard C, Pochon C, Schneider P, Simon N, et al. Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)]. Bull Cancer. 2025;112:S135\u2013S145.","journal-title":"Bull Cancer"},{"key":"2685_CR117","doi-asserted-by":"crossref","unstructured":"Gibson BES, Sauer MG, Amrolia P. Acute myeloid leukemia in children. In: Carreras E, Dufour C, Mohty M, Kroger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Springer, Cham; 2019. p. 523\u201330.","DOI":"10.1007\/978-3-030-02278-5_70"},{"key":"2685_CR118","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMoa1200503","volume":"367","author":"JM Venstrom","year":"2012","unstructured":"Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367:805\u201316.","journal-title":"N Engl J Med"},{"key":"2685_CR119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.imlet.2013.09.027","volume":"155","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, Bauquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of alpha\/beta+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett. 2013;155:21\u201323.","journal-title":"Immunol Lett"},{"key":"2685_CR120","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/leu.2017.151","volume":"31","author":"E Bernson","year":"2017","unstructured":"Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydstrom A, et al. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia. 2017;31:2552\u20139.","journal-title":"Leukemia"},{"key":"2685_CR121","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12865-023-00548-1","volume":"24","author":"T Bakhtiari","year":"2023","unstructured":"Bakhtiari T, Ahmadvand M, Yaghmaie M, Sadeghi A, Mousavi SA, Rostami T, et al. Investigation of KIR\/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML). BMC Immunol. 2023;24:10.","journal-title":"BMC Immunol"},{"key":"2685_CR122","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/bloodadvances.2019001284","volume":"4","author":"MR Verneris","year":"2020","unstructured":"Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, et al. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020;4:1350\u20136.","journal-title":"Blood Adv"},{"key":"2685_CR123","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1182\/bloodadvances.2023010281","volume":"7","author":"JC Fierro-Pineda","year":"2023","unstructured":"Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023;7:5639\u201348.","journal-title":"Blood Adv"},{"key":"2685_CR124","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956\u201362.","journal-title":"Blood"},{"key":"2685_CR125","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2014.09.009","volume":"29","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Bayraktar UD. No donor\u201d? Consider a haploidentical transplant. Blood Rev. 2015;29:63\u201370.","journal-title":"Blood Rev"},{"key":"2685_CR126","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/j.bbmt.2016.09.004","volume":"22","author":"XD Mo","year":"2016","unstructured":"Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation in first complete remission can abrogate the poor outcomes of children with acute myeloid leukemia resistant to the first course of induction chemotherapy. Biol Blood Marrow Transplant. 2016;22:2235\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR127","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood.2023021336","volume":"143","author":"P Merli","year":"2024","unstructured":"Merli P, Algeri M, Galaverna F, Bertaina V, Lucarelli B, Boccieri E, et al. TCRalphabeta\/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis. Blood. 2024;143:279\u201389.","journal-title":"Blood"},{"key":"2685_CR128","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00277-024-05737-5","volume":"103","author":"BK Kim","year":"2024","unstructured":"Kim BK, Hong KT, Choi JY, Kim H, Park HJ, Kang HJ. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients. Ann Hematol. 2024;103:2051\u20138.","journal-title":"Ann Hematol"},{"key":"2685_CR129","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/stcltm\/szac079","volume":"12","author":"J Kurtzberg","year":"2023","unstructured":"Kurtzberg J, Troy JD, Page KM, El Ayoubi HR, Volt F, Maria Scigliuolo G, et al. Unrelated donor cord blood transplantation in children: lessons learned over 3 decades. Stem Cells Transl Med. 2023;12:26\u201338.","journal-title":"Stem Cells Transl Med"},{"key":"2685_CR130","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021;14:12.","journal-title":"J Hematol Oncol"},{"key":"2685_CR131","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/petr.12475","volume":"19","author":"X Tang","year":"2015","unstructured":"Tang X, Chen J, Fang J, Sun X, Qin MQ, Li J, et al. Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China. Pediatr Transplant. 2015;19:413\u201321.","journal-title":"Pediatr Transplant"},{"key":"2685_CR132","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00277-014-2213-y","volume":"94","author":"C Zheng","year":"2015","unstructured":"Zheng C, Zhu X, Tang B, Yao W, Song K, Tong J, et al. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia. Ann Hematol. 2015;94:473\u201380.","journal-title":"Ann Hematol"},{"key":"2685_CR133","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.bbmt.2016.08.004","volume":"22","author":"S Visentin","year":"2016","unstructured":"Visentin S, Auquier P, Bertrand Y, Baruchel A, Tabone MD, Pochon C, et al. The impact of donor type on long-term health status and quality of life after allogeneic hematopoietic stem cell transplantation for childhood acute leukemia: a Leucemie de l\u2019Enfant et de L\u2019Adolescent Study. Biol Blood Marrow Transplant. 2016;22:2003\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR134","first-page":"549","volume":"42","author":"EL Chen","year":"2021","unstructured":"Chen EL, Liu HL, Geng LQ, Tang BL, Zhu XY, Yao W, et al. [Unrelated cord blood stem cell transplantation for high-risk\/refractory childhood acute myeloid leukemia: a clinical analysis of 160 cases]. Zhonghua Xue Ye Xue Za Zhi. 2021;42:549\u201354.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2685_CR135","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood.2019001212","volume":"134","author":"J Dehn","year":"2019","unstructured":"Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR. Blood. 2019;134:924\u201334.","journal-title":"Blood"},{"key":"2685_CR136","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.jtct.2024.06.028","volume":"30","author":"MM Rivera-Franco","year":"2024","unstructured":"Rivera-Franco MM, Wynn L, Volt F, Hernandez D, Cappelli B, Scigliuolo GM, et al. Unsupervised clustering analysis of regimen and HLA characteristics in pediatric umbilical cord blood transplantation. Transplant Cell Ther. 2024;30:910.e1\u201315.","journal-title":"Transplant Cell Ther"},{"key":"2685_CR137","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1182\/bloodadvances.2018025908","volume":"3","author":"AK Keating","year":"2019","unstructured":"Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, et al. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Adv. 2019;3:1118\u201328.","journal-title":"Blood Adv"},{"key":"2685_CR138","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1182\/bloodadvances.2022009253","volume":"7","author":"C Horgan","year":"2023","unstructured":"Horgan C, Mullanfiroze K, Rauthan A, Patrick K, Butt NA, Mirci-Danicar O, et al. T-cell replete cord transplants give superior outcomes in high-risk and relapsed\/refractory pediatric myeloid malignancy. Blood Adv. 2023;7:2155\u201365.","journal-title":"Blood Adv"},{"key":"2685_CR139","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bbmt.2016.11.022","volume":"23","author":"G Lucchini","year":"2017","unstructured":"Lucchini G, Labopin M, Beohou E, Dalissier A, Dalle JH, Cornish J, et al. Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:467\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR140","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/pbc.24524","volume":"60","author":"A Shinzato","year":"2013","unstructured":"Shinzato A, Tabuchi K, Atsuta Y, Inoue M, Inagaki J, Yabe H, et al. PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA-matched sibling donor. Pediatr Blood Cancer. 2013;60:1513\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR141","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396.","journal-title":"N Engl J Med"},{"key":"2685_CR142","doi-asserted-by":"crossref","unstructured":"Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Diaz-Fernandez P, et al. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nat Biotechnol. 2024;43:1\u201312.","DOI":"10.1038\/s41587-024-02348-3"},{"key":"2685_CR143","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR144","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/pbc.25389","volume":"62","author":"H Ishida","year":"2015","unstructured":"Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, et al. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and\/or busulfan in acute myeloid leukemia in Japanese children and adolescents. Pediatr Blood Cancer. 2015;62:883\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR145","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.bbmt.2017.05.009","volume":"23","author":"D Tomizawa","year":"2017","unstructured":"Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, et al. Allogeneic hematopoietic stem cell transplantation for adolescents and young adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23:1515\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR146","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.bbmt.2017.06.002","volume":"23","author":"LM Burroughs","year":"2017","unstructured":"Burroughs LM, Shimamura A, Talano JA, Domm JA, Baker KK, Delaney C, et al. Allogeneic hematopoietic cell transplantation using Treosulfan-based conditioning for treatment of marrow failure disorders. Biol Blood Marrow Transplant. 2017;23:1669\u201377.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR147","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2016.01.019","volume":"22","author":"S Zahler","year":"2016","unstructured":"Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, et al. A phase I study of reduced-intensity conditioning and allogeneic stem cell transplantation followed by dose escalation of targeted consolidation immunotherapy with gemtuzumab ozogamicin in children and adolescents with CD33+ acute myeloid leukemia. Biol Blood Marrow Transplant. 2016;22:698\u2013704.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR148","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1182\/blood-2013-10-535716","volume":"123","author":"M Bitan","year":"2014","unstructured":"Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123:1615\u201320.","journal-title":"Blood"},{"key":"2685_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00415-23","volume":"11","author":"S McMahon","year":"2023","unstructured":"McMahon S, Sahasrabhojane P, Kim J, Franklin S, Chang CC, Jenq RR, et al. Contribution of the oral and gastrointestinal microbiomes to bloodstream infections in leukemia patients. Microbiol Spectr. 2023;11:e0041523.","journal-title":"Microbiol Spectr"},{"key":"2685_CR150","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/bloodadvances.2021005129","volume":"5","author":"R Masetti","year":"2021","unstructured":"Masetti R, Muratore E, Leardini D, Zama D, Turroni S, Brigidi P, et al. Gut microbiome in pediatric acute leukemia: from predisposition to cure. Blood Adv. 2021;5:4619\u201329.","journal-title":"Blood Adv"},{"key":"2685_CR151","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood.2023020026","volume":"142","author":"R Masetti","year":"2023","unstructured":"Masetti R, Leardini D, Muratore E, Fabbrini M, D\u2019Amico F, Zama D, et al. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children. Blood. 2023;142:1387\u201398.","journal-title":"Blood"},{"key":"2685_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2024.101955","volume":"72","author":"P Jozefczuk","year":"2024","unstructured":"Jozefczuk P, Bilinski J, Minkowska A, Laguna P. Gut microbiome in children undergoing hematopoietic stem cell transplantation. Best Pract Res Clin Gastroenterol. 2024;72:101955.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2685_CR153","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41409-019-0438-z","volume":"54","author":"A Dahlberg","year":"2019","unstructured":"Dahlberg A, Leisenring W, Bleakley M, Meshinchi S, Baker KS, Summers C, et al. Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children. Bone Marrow Transplant. 2019;54:1337\u201345.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR154","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bbmt.2014.03.028","volume":"20","author":"NN Shah","year":"2014","unstructured":"Shah NN, Borowitz MJ, Steinberg SM, Robey NC, Gamper CJ, Symons HJ, et al. Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1033\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR155","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.bmt.1704321","volume":"33","author":"E Gorczynska","year":"2004","unstructured":"Gorczynska E, Turkiewicz D, Toporski J, Kalwak K, Rybka B, Ryczan R, et al. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children. Bone Marrow Transplant. 2004;33:211\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR156","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","volume":"118","author":"E Rettinger","year":"2011","unstructured":"Rettinger E, Willasch AM, Kreyenberg H, Borkhardt A, Holter W, Kremens B, et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood. 2011;118:5681\u20138.","journal-title":"Blood"},{"key":"2685_CR157","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/sj.bmt.1704444","volume":"33","author":"P Bader","year":"2004","unstructured":"Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D, et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant. 2004;33:815\u201321.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR158","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184\u201391.","journal-title":"Mol Ther"},{"key":"2685_CR159","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637\u201347.","journal-title":"Leukemia"},{"key":"2685_CR160","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"I Pizzitola","year":"2014","unstructured":"Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28:1596\u2013605.","journal-title":"Leukemia"},{"key":"2685_CR161","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25:1064\u201372.","journal-title":"Nat Med"},{"key":"2685_CR162","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","volume":"131","author":"RG Dossa","year":"2018","unstructured":"Dossa RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, Biernacki MA, Foster K, et al. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood. 2018;131:108\u201320.","journal-title":"Blood"},{"key":"2685_CR163","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","volume":"7","author":"R Nguyen","year":"2019","unstructured":"Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7:81.","journal-title":"J Immunother Cancer"},{"key":"2685_CR164","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3389\/fimmu.2019.01218","volume":"10","author":"M Bremm","year":"2019","unstructured":"Bremm M, Pfeffermann LM, Cappel C, Katzki V, Erben S, Betz S, et al. Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells. Front Immunol. 2019;10:1218.","journal-title":"Front Immunol"},{"key":"2685_CR165","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38:4249\u201359.","journal-title":"J Clin Oncol"},{"key":"2685_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27284","volume":"65","author":"A Tamura","year":"2018","unstructured":"Tamura A, Ishida T, Saito A, Yamamoto N, Yokoi T, Uemura S, et al. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2018;65:e27284.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR167","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1200\/JCO.21.01612","volume":"40","author":"JA Pollard","year":"2022","unstructured":"Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the Children\u2019s Oncology Group Protocol AAML1031. J Clin Oncol. 2022;40:2023\u201335.","journal-title":"J Clin Oncol"},{"key":"2685_CR168","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/17474086.2024.2382300","volume":"17","author":"C Alati","year":"2024","unstructured":"Alati C, Pitea M, Mico MC, Marafioti V, Greve B, Pratico G, et al. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024? Expert Rev Hematol. 2024;17:515\u201325.","journal-title":"Expert Rev Hematol"},{"key":"2685_CR169","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10:e600\u2013e611.","journal-title":"Lancet Haematol"},{"key":"2685_CR170","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12185-022-03352-6","volume":"116","author":"F Biavasco","year":"2022","unstructured":"Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022;116:341\u201350.","journal-title":"Int J Hematol"},{"key":"2685_CR171","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11864-022-00952-6","volume":"23","author":"J Senapati","year":"2022","unstructured":"Senapati J, Kadia TM. Which FLT3 inhibitor for treatment of AML? Curr Treat Options Oncol. 2022;23:359\u201380.","journal-title":"Curr Treat Options Oncol"},{"key":"2685_CR172","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766\u201375.","journal-title":"J Clin Oncol"},{"key":"2685_CR173","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/pbc.25437","volume":"62","author":"K Tarlock","year":"2015","unstructured":"Tarlock K, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, et al. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3\/ITD acute myeloid leukemia. Pediatr Blood Cancer. 2015;62:1048\u201354.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR174","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.bbmt.2003.08.003","volume":"9","author":"S Meshinchi","year":"2003","unstructured":"Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2003;9:706\u201313.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR175","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pbc.25866","volume":"63","author":"T Taga","year":"2016","unstructured":"Taga T, Murakami Y, Tabuchi K, Adachi S, Tomizawa D, Kojima Y, et al. Role of second transplantation for children with acute myeloid leukemia following posttransplantation relapse. Pediatr Blood Cancer. 2016;63:701\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR176","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","volume":"24","author":"I Yaniv","year":"2018","unstructured":"Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP Study. Biol Blood Marrow Transplant. 2018;24:1629\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2685_CR177","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjh.16441","volume":"189","author":"T Uden","year":"2020","unstructured":"Uden T, Bertaina A, Abrahamsson J, Ansari M, Balduzzi A, Bourquin JP, et al. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children. Br J Haematol. 2020;189:745\u201350.","journal-title":"Br J Haematol"},{"key":"2685_CR178","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood.V75.10.1932.1932","volume":"75","author":"U Creutzig","year":"1990","unstructured":"Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood. 1990;75:1932\u201340.","journal-title":"Blood"},{"key":"2685_CR179","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1038\/sj.leu.2403920","volume":"19","author":"U Creutzig","year":"2005","unstructured":"Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030\u201342.","journal-title":"Leukemia"},{"key":"2685_CR180","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1055\/s-0035-1548816","volume":"227","author":"U Creutzig","year":"2015","unstructured":"Creutzig U, Dworzak M, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, et al. Randomised introduction of 2-CDA as intensification during consolidation for children with high-risk AML-results from Study AML-BFM 2004. Klin Padiatr. 2015;227:116\u201322.","journal-title":"Klin Padiatr"},{"key":"2685_CR181","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1038\/leu.2017.121","volume":"31","author":"M Rasche","year":"2017","unstructured":"Rasche M, von Neuhoff C, Dworzak M, Bourquin JP, Bradtke J, Gohring G, et al. Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004. Leukemia. 2017;31:2807\u201314.","journal-title":"Leukemia"},{"key":"2685_CR182","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","volume":"122","author":"U Creutzig","year":"2013","unstructured":"Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122:37\u201343.","journal-title":"Blood"},{"key":"2685_CR183","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","volume":"32","author":"M Rasche","year":"2018","unstructured":"Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167\u201377.","journal-title":"Leukemia"},{"key":"2685_CR184","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","volume":"129","author":"M Uffmann","year":"2017","unstructured":"Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017;129:3314\u201321.","journal-title":"Blood"},{"key":"2685_CR185","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","volume":"101","author":"CM Zwaan","year":"2003","unstructured":"Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink JP, Tissing WJ, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101:3868\u201371.","journal-title":"Blood"},{"key":"2685_CR186","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1055\/s-0034-1385918","volume":"226","author":"U Creutzig","year":"2014","unstructured":"Creutzig U, Semmler J, Kaspers GL, Reinhardt D, Zimmermann M. Re-induction with L-DNR\/FLAG improves response after AML relapse, but not long-term survival. Klin Padiatr. 2014;226:323\u201331.","journal-title":"Klin Padiatr"},{"key":"2685_CR187","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3324\/haematol.2018.191841","volume":"104","author":"N Niktoreh","year":"2019","unstructured":"Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, et al. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group. Haematologica. 2019;104:120\u20137.","journal-title":"Haematologica"},{"key":"2685_CR188","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/a-0750-5963","volume":"230","author":"U Creutzig","year":"2018","unstructured":"Creutzig U, Dworzak M, von Neuhoff N, Rasche M, Reinhardt D. [Acute promyelocytic leukemia: new treatment strategies with ATRA and ATO\u2014AML-BFM-recommendations]. Klin Padiatr. 2018;230:299\u2013304.","journal-title":"Klin Padiatr"},{"key":"2685_CR189","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1609128","volume":"2019","author":"N Niktoreh","year":"2019","unstructured":"Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M, et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019;2019:1609128.","journal-title":"J Oncol"},{"key":"2685_CR190","doi-asserted-by":"crossref","unstructured":"Rasche M, Steidel E, Zimmermann M, Bourquin JP, Boztug H, Janotova I, et al. Second relapse of pediatric patients with acute myeloid leukemia: a report on current treatment strategies and outcome of the AML-BFM Study Group. Cancers. 2021;13:789.","DOI":"10.3390\/cancers13040789"},{"key":"2685_CR191","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s002770100304","volume":"80","author":"G Mann","year":"2001","unstructured":"Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol. 2001;80:417\u201322.","journal-title":"Ann Hematol"},{"key":"2685_CR192","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/leu.2011.267","volume":"26","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012;26:654\u201361.","journal-title":"Leukemia"},{"key":"2685_CR193","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27089","volume":"65","author":"U Creutzig","year":"2018","unstructured":"Creutzig U, Kutny MA, Barr R, Schlenk RF, Ribeiro RC. Acute myelogenous leukemia in adolescents and young adults. Pediatr Blood Cancer. 2018;65:e27089.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR194","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/bmt.2015.82","volume":"50","author":"SD Goyal","year":"2015","unstructured":"Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, et al. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015;50:1057\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR195","doi-asserted-by":"publisher","unstructured":"Stove HK, Sandahl JD, Abrahamsson J, Asdahl PH, Forestier E, Ha SY, et al. Extramedullary leukemia in children with acute myeloid leukemia: a population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Pediatr Blood Cancer. 2017;64. https:\/\/doi.org\/10.1002\/pbc.26520.","DOI":"10.1002\/pbc.26520"},{"key":"2685_CR196","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/00043426-200310000-00004","volume":"25","author":"KE Dusenbery","year":"2003","unstructured":"Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children\u2019s Cancer Group. J Pediatr Hematol Oncol. 2003;25:760\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2685_CR197","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12185-014-1616-9","volume":"100","author":"H Nakayama","year":"2014","unstructured":"Nakayama H, Tabuchi K, Tawa A, Tsukimoto I, Tsuchida M, Morimoto A, et al. Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol. Int J Hematol. 2014;100:171\u20139.","journal-title":"Int J Hematol"},{"key":"2685_CR198","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.14720","volume":"178","author":"L Karlsson","year":"2017","unstructured":"Karlsson L, Forestier E, Hasle H, Jahnukainen K, Jonsson OG, Lausen B, et al. Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. Br J Haematol. 2017;178:592\u2013602.","journal-title":"Br J Haematol"},{"key":"2685_CR199","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/MPH.0b013e31816e2342","volume":"30","author":"F Fagioli","year":"2008","unstructured":"Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P, et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol. 2008;30:575\u201383.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2685_CR200","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/sj.leu.2401254","volume":"13","author":"DK Webb","year":"1999","unstructured":"Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia. 1999;13:25\u201331.","journal-title":"Leukemia"},{"key":"2685_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28736","volume":"68","author":"H Moritake","year":"2021","unstructured":"Moritake H, Tanaka S, Miyamura T, Nakayama H, Shiba N, Shimada A, et al. The outcomes of relapsed acute myeloid leukemia in children: results from the Japanese Pediatric Leukemia\/Lymphoma Study Group AML-05R study. Pediatr Blood Cancer. 2021;68:e28736.","journal-title":"Pediatr Blood Cancer"},{"key":"2685_CR202","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1200\/JCO.2003.11.066","volume":"21","author":"N Aladjidi","year":"2003","unstructured":"Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89\/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21:4377\u201385.","journal-title":"J Clin Oncol"},{"key":"2685_CR203","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2003.06.128","volume":"21","author":"RJ Wells","year":"2003","unstructured":"Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children\u2019s Cancer Group Study 2951. J Clin Oncol. 2003;21:2940\u20137.","journal-title":"J Clin Oncol"},{"key":"2685_CR204","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/(SICI)1096-911X(199906)32:6<411::AID-MPO3>3.0.CO;2-K","volume":"32","author":"AJ McCarthy","year":"1999","unstructured":"McCarthy AJ, Pitcher LA, Hann IM, Oakhill A. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol. 1999;32:411\u20135.","journal-title":"Med Pediatr Oncol"},{"key":"2685_CR205","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/bmt.2014.246","volume":"50","author":"F Locatelli","year":"2015","unstructured":"Locatelli F, Masetti R, Rondelli R, Zecca M, Fagioli F, Rovelli A, et al. Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002\/01 study. Bone Marrow Transplant. 2015;50:181\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2685_CR206","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.bbmt.2018.09.016","volume":"25","author":"TC Lund","year":"2019","unstructured":"Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia. Biol Blood Marrow Transplant. 2019;25:301\u20136.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02685-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02685-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02685-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:05:51Z","timestamp":1758791151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02685-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":206,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02685-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KK acknowledges research support from Jazz Pharmaceuticals, travel grants from Sobi and Medac, and receives honoraria from Vertex. BG declares honoraria from Vertex. JHK acknowledges advisory roles with Bluebird Bio, Novartis, Roche, and Jazz Pharmaceuticals. FL participated in advisory boards for Amgen, Sanofi, and Vertex; speaker\u2019s bureau for Amgen, Gilead, Miltenyi, Novartis, Sanofi, and SOBI. All other authors declare that the manuscript was written in the absence of any commercial or financial relationships that could be perceived as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}